GENEVA, SWITZERLAND / ACCESSWIRE / October 21, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) ...

Relief Therapeutics to receive European patent covering RLF-TD011 for epidermolysis bullosa wound treatment: Geneva Tuesday, October 22, 2024, 13:00 Hrs [IST] Relief Therapeutics ...

Hyperammonemia Treatment MarketThe global hyperammonemia treatment market size is expected to reach a valuation of USD ...

The Swiss market recently exhibited a mixed performance, with the benchmark SMI index experiencing fluctuations and closing slightly lower, while some companies like Relief Therapeutics saw ...

Relief Therapeutics Holding SA, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The firm says it could offer an alternative to existing treatments while sidestepping addiction concerns that have plagued ...

That’s why we all work at Terray,” said Jacob Berlin, Ph.D, co-founder and CEO of Terray Therapeutics. “Knowledge of what ...

Zylem Biosciences, a company specializing in cancer and cardiovascular therapeutics, announced that Northwestern University has filed a lawsuit against Moderna, alleging infringement of key patents ...

Revance Therapeutics, Inc. (NASDAQ: RVNC )'s sale to Crown Laboratories, Inc. for $6.66 per share in cash. If you are a Revance shareholder, click here to learn more about your rights and options .

Terray Therapeutics has raked in $120 million for a series B fundraise as the AI-focused biotech aims to transform small ...